---
figid: PMC4986142__nihms747168f1
figlink: /pmc/articles/PMC4986142/figure/F1/
number: F1
caption: Mechanisms of resistance to RAF inhibitors. Before exposure to RAF inhibitors,
  BRAFV600E-mutant tumors have hyperactivated ERK signaling. This results in negative-feedback
  suppression of upstream receptor tyrosine kinase signaling. In this state, expression
  of active RAS-GTP is low and BRAFV600E signals as a monomer, which is sensitive
  to RAF inhibitors. Upon treatment with vemurafenib, ERK-dependent negative feedback
  is rapidly downregulated, resulting in the restoration of receptor signaling, RAS
  activation, induction of RAF dimers, and activation of parallel signaling pathways,
  including the PI3K–AKT pathway. Activation of PI3K/AKT, which coregulates the expression
  of some downstream effectors of ERK transformation including D cyclins, results
  in diminished dependence of RAF signaling. This rapid adaptive response to RAF inhibition
  attenuates the antitumor effects of RAF inhibitors and thus may promote the selection
  of subclones harboring coalterations that confer higher levels of RAF inhibitor
  resistance. These molecular alterations include NRAS and KRAS mutations, loss of
  NF1 function, aberrantly spliced BRAF variants that lack the RAS binding domain,
  BRAF amplification, and mutations in MEK1 and MEK2, among others.
pmcid: PMC4986142
papertitle: Towards a Unified Model of RAF Inhibitor Resistance.
reftext: David B. Solit, et al. Cancer Discov. ;4(1):27-30.
pmc_ranked_result_index: '41737'
pathway_score: 0.9714785
filename: nihms747168f1.jpg
figtitle: Resistance to RAF inhibitors
year: ''
organisms: Homo sapiens
ndex: f86adef7-debd-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4986142__nihms747168f1.html
  '@type': Dataset
  description: Mechanisms of resistance to RAF inhibitors. Before exposure to RAF
    inhibitors, BRAFV600E-mutant tumors have hyperactivated ERK signaling. This results
    in negative-feedback suppression of upstream receptor tyrosine kinase signaling.
    In this state, expression of active RAS-GTP is low and BRAFV600E signals as a
    monomer, which is sensitive to RAF inhibitors. Upon treatment with vemurafenib,
    ERK-dependent negative feedback is rapidly downregulated, resulting in the restoration
    of receptor signaling, RAS activation, induction of RAF dimers, and activation
    of parallel signaling pathways, including the PI3K–AKT pathway. Activation of
    PI3K/AKT, which coregulates the expression of some downstream effectors of ERK
    transformation including D cyclins, results in diminished dependence of RAF signaling.
    This rapid adaptive response to RAF inhibition attenuates the antitumor effects
    of RAF inhibitors and thus may promote the selection of subclones harboring coalterations
    that confer higher levels of RAF inhibitor resistance. These molecular alterations
    include NRAS and KRAS mutations, loss of NF1 function, aberrantly spliced BRAF
    variants that lack the RAS binding domain, BRAF amplification, and mutations in
    MEK1 and MEK2, among others.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R3
  - MAP2K1
  - MAP2K2
  - PIK3CG
  - BRAF
  - GRB2
  - PIK3CD
  - ARAF
  - RAF1
  - PTEN
  - SPRY1
  - PIK3R6
  - MAPK1
  - MAPK3
  - NF1
  - AKT2
  - SPRY4
  - PIK3CA
  - AKT3
  - HRAS
  - KRAS
  - SPRY2
  - PIK3R5
  - PIK3CB
  - SPRY3
  - SOS1
  - PIK3R4
  - AKT1
  - SOS2
  - NRAS
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: SPRY
  symbol: SPRY
  source: bioentities_symbol
  hgnc_symbol: SPRY1
  entrez: '10252'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: SPRY
  symbol: SPRY
  source: bioentities_symbol
  hgnc_symbol: SPRY4
  entrez: '81848'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: SPRY
  symbol: SPRY
  source: bioentities_symbol
  hgnc_symbol: SPRY2
  entrez: '10253'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: SPRY
  symbol: SPRY
  source: bioentities_symbol
  hgnc_symbol: SPRY3
  entrez: '10251'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4986142__F1
redirect_from: /figures/PMC4986142__F1
figtype: Figure
---
